Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapt Therapeutics Inc (NQ: RAPT )

1.050 -0.020 (-1.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rapt Therapeutics Inc

< Previous 1 2 3 4 5 Next >
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Down 3%; Aramark Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Nasdaq Moves Lower; Canaan Shares Surge
Via Benzinga
RAPT Therapeutics: Q4 Earnings Insights
Via Benzinga
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury
RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus. 
Via Benzinga
Exposures Product Safety
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure. 
Via Benzinga
Exposures Product Safety
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
RAPT Therapeutics Reports First Quarter 2024 Financial Results
Company maintains solid cash position of $141.6 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
From RAPT Therapeutics, Inc.
Via GlobeNewswire
3 Biotech Stocks to Dump Before They Go to Zero
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling. 
Via InvestorPlace
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Company maintains solid cash position of $158.9 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Rivian Automotive Reports Q4 Loss, Joins Etsy, Lucid Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday. 
Via Benzinga
What's Going On With RAPT Therapeutics Stock On Wednesday?
Latest developments in RAPT Therapeutics as FDA places clinical hold on Phase 2b trial for zelnecirnon in dermatitis and asthma. Stock rebounds and analyst downgrades. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.